The benign treatment-related imaging changes may pose a challenge in appropriate clinical decision making for the neuro-oncologists. The post-treatment changes are usually benign and differ largely in management approach from a progressive tumor. In this study, 304 glioblastoma patients were evaluated retrospectively to study the ability of radiomic analysis to distinguish the post-treatment changes from a truly progressive disease. 3D volumetrics using 3D Slicer 4.3.1 and texture analysis of the lesions were performed. On LOOCV, sensitivity and specificity of 97% and 72% were obtained respectively. We concluded that radiomics can differentiate between the progressive disease and pseudo-progression in glioblastoma patients.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords